Skip to content Skip to footer

Promising New Antibiotic Approved as Battle Against Drug-Resistant UTIs Continues

UCI Health has made headlines with the recent approval by the Food and Drug Administration of Pivmecillinam, an antibiotic used in Europe for decades, to treat urinary tract infections (UTIs) in the United States. UTIs are a common but persistent health issue, challenging to treat due to increasing bacterial resistance against currently available antibiotic remedies.

Amidst the growing threat of drug-resistant bacteria, it is the advice of Dr. Shruti Gohil, a UCI Health infectious disease expert, that this newly approved drug should be prescribed judiciously. Dr. Gohil expressed her optimism about the potential impact of the new drug on the treatment landscape, calling it ‘an exciting new possibility for the treatment of lower urinary tract infections.’ However, she strongly emphasized the need for responsible usage to avoid potential bacterial resistance against this new antibiotic.

In addition to her cautious optimism about Pivmecillinam, Dr. Gohil recently contributed to two studies that propose an effective method for refining antibiotic selection in hospital patients suffering from pneumonia or UTIs. The studies aim to foster better antibiotic stewardship within hospital settings, contributing to ongoing efforts in preventing drug-resistant infections. Both studies were published in the esteemed Journal of the American Medical Association (JAMA).

Equipped with board certification in infectious disease and dual roles as the Associate Medical Director for UCI Health Epidemiology and Infection Prevention, and an Assistant Professor at the UCI School of Medicine, Dr. Gohil is well-versed in the complexities of infection prevention. Her varied clinical interests span across hospital epidemiology, communicable disease transmission, and multidrug-resistant organism infections.

In the changing landscape of the COVID-19 pandemic, Dr. Gohil led the UCI Health response. Her responsibilities included clinical and epidemiologic assessment of healthcare providers and patients, implementing COVID-19 testing and vaccination, and designing exposure definition and response strategies. She also guided the institution in executing successful contact tracing, vaccination, and infection prevention strategies to curb viral spread.

In collaboration with several national studies, Dr. Gohil continues her pursuit of safer patient experiences, particularly in cases of potential multidrug-resistant bacterial infections. Specifically, she advocates for limiting the use of extended-spectrum antibacterial drugs in real-time clinical scenarios.


Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]